Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest Position

Velan Capital Investment Management LP boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 50.0% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 300,000 shares of the company's stock after acquiring an additional 100,000 shares during the quarter. Zevra Therapeutics accounts for about 2.2% of Velan Capital Investment Management LP's investment portfolio, making the stock its 9th largest position. Velan Capital Investment Management LP owned 0.56% of Zevra Therapeutics worth $2,502,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new stake in Zevra Therapeutics in the fourth quarter valued at approximately $53,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Zevra Therapeutics in the 4th quarter worth $94,000. Squarepoint Ops LLC raised its position in shares of Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after buying an additional 4,384 shares in the last quarter. ProShare Advisors LLC bought a new stake in shares of Zevra Therapeutics during the 4th quarter worth $145,000. Finally, Invesco Ltd. grew its position in Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock worth $153,000 after acquiring an additional 3,007 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company's stock.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director John B. Bode acquired 10,000 shares of the firm's stock in a transaction on Wednesday, March 19th. The shares were purchased at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the transaction, the director now owns 40,000 shares of the company's stock, valued at $318,400. The trade was a 33.33% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on ZVRA. JMP Securities set a $18.00 price target on Zevra Therapeutics in a research note on Wednesday, March 12th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday. Canaccord Genuity Group upped their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $22.29.

Zevra Therapeutics Price Performance

ZVRA opened at $8.66 on Monday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The stock's 50 day simple moving average is $7.54 and its 200 day simple moving average is $8.07. The firm has a market cap of $473.52 million, a price-to-earnings ratio of -4.40 and a beta of 1.87. Zevra Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $20.40 million for the quarter, compared to analysts' expectations of $16.96 million. During the same quarter last year, the business earned ($0.40) earnings per share. As a group, analysts predict that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.